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Abstract: The aim of this review is to analyze the latest trends in the management of non- 
vestibular skull base and intracranial schwannomas in order to optimize tumor control and 
quality of life. Non-vestibular cranial nerve schwannomas are rare lesions, representing 
5–10% of cranial nerve schwannomas. Management decisions should be individualized depend-
ing on tumor size, location and associated functional deficits. Generally, large sized schwanno-
mas exerting significant mass effect with increased intracranial pressure are treated surgically. In 
some cases, even after optimal skull base resection, it is not possible to achieve a gross total 
resection because tumor location and extent and/or to reduce morbidity. Thus, subtotal resection 
followed by stereotactic radiosurgery or fractioned radiotherapy offers an alternative approach. 
In certain cases, stereotactic radiosurgery or radiotherapy alone achieves good tumor control 
rates and less morbidity to gross total resection. Finally, given the slow growth rate of most of 
these tumors, observation with periodic radiographic follow-up approach is also a reasonable 
alternative for small tumors with few, if any, symptoms. 
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Introduction
Schwannomas are primary peripheral nervous system tumors arising from Schwann 
cells. Schwann cells function to myelinate peripheral nerves beginning at the 
Obersteiner-Redlich zone, the transition from the central to the peripheral nervous 
system.1 They may originate from any peripheral, cranial or autonomic nerve. 
Schwannomas are usually solitary neoplasms; multifocal presentation should raise 
the suspicion for neurofibromatosis type 1 and type 2 or schwannomatosis.2
Sporadic non-vestibular cranial nerve schwannomas (NVCNS) are rare lesions, 
representing 5–10% of cranial nerve schwannomas.3 Nerve sheath tumors account for 
8% of primary intracranial tumors and more than 90% of intracranial nerve sheath 
tumors are vestibular schwannomas (VS).4,5 In descending frequency, NVCNS involve 
the trigeminal nerve, lower CNs, the facial nerve and lastly the oculomotor nerves.
NVCNS are characterized by slow growth. It has been estimated that over 50% 
of the NVCNS exhibit an annual growth rate of more than 5% of the initial volume. 
This ratio is higher than in sporadic vestibular schwannomas, but lower than in 
patients with neurofibromatosis type 2 (NF2).6 Schwannomas usually remain 
benign, however there is a possibility of malignant transformation mainly in the 
setting of neurofibromatosis type 1 (NF1).5,7,8
The morbidity associated with skull base and intracranial schwannomas and 
their treatment has decreased with the improvement of open surgical approaches to 
Correspondence: Carlos Suárez  
Instituto de Investigación Sanitaria del Principado 
de Asturias and CIBERONC, ISCIII, Avenida de 
Roma s/n, Oviedo 33011, Spain  
Email csuareznieto@gmail.com   
Fernando López  
Department of Otorhinolaryngology, Hospital 
Universitario Central de Asturias, Avenida de 
Roma s/n, Oviedo 33011, Spain  
Email flopez_1981@yahoo.es
submit your manuscript | www.dovepress.com Cancer Management and Research 2021:13 463–478                                                        463
http://doi.org/10.2147/CMAR.S287410 
DovePress © 2021 Suárez et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms. 
php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the 
work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For 
permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Cancer Management and Research                                                       Dovepress
open access to scientific and medical research



































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1
the skull base and with the development of endoscopic 
skull base surgery. However, the morbidity of resection is 
still relatively high depending on the size and location of 
the tumor.
The purpose of this review is to discuss the latest 
trends in the management of these lesions in order to 
optimize disease control and quality of life.
Trigeminal Schwannomas (TS)
Epidemiology
TS are a rare entity, accounting for 0.07–1% of all 
intracranial tumors. However, these tumors are 
the second most common intracranial schwannomas, 
after VS, and account for 3–9% of intracranial 
schwannomas.9–11 While most TS develop in the 
Gasserian ganglion within the middle fossa, TS can 
occur anywhere along the course of the trigeminal 
root, ganglion, and peripheral branches. Malignant TS 
are rare. Only 22 cases of histologically malignant TS 
have been reported in the literature.12 A review of 514 
patients surgically treated for TS reported malignancy in 
1.5% of them.9
Classification Systems
Several classification systems of TS have been employed, 
some of them are similar. The original classification of 
these tumors by Jefferson includes type A (mainly in the 
middle fossa), type B (mainly in the posterior fossa) and 
type C (dumbbell type, in both the middle and posterior 
fossae).13 Type D was added later and includes those 
arising from one of the three divisions of the trigeminal 
nerve.12,14,15 In a review of 455 cases the following inci-
dence was observed: 40% type A, 22% type B, 32% type 
C and 6% type D.9 A more complex classification into 6 
different types has been proposed by Yoshida and 
Kawase:16 type P (posterior fossa tumor); type 
M (middle fossa tumor); type E (extracranial tumor). The 
other 3 types refer to dumbbell type tumors in multiple 
fossae: type MP (middle and posterior fossae); type ME 
(middle fossa and extracranial space); type MPE (posterior 
fossa, middle fossa, and extracranial space). Employing 
this system, Yoshida and Kawase reported the location of 
429 tumors: type M 38.5%; type P 23.5%; type E 5.4%; 
type MP 28.3%; type ME 3.5%; and type MPE 0.7%.16 In 
summary, TS arising in the middle fossa are the most 
common.
Symptoms and Signs
Trigeminal nerve dysfunction is seen in most patients. The 
most common trigeminal nerve symptoms are pain, par-
esthesia, numbness and decreased motor function. 
Symptoms and signs are reflected in Table 1.9–12,15–20 
However, it has been reported that up to 18% of tumors 
can be found incidentally with magnetic resonance (MR) 
imaging performed for other reasons.16
Management
Surgical resection is the mainstay of management, 
although the therapeutic modality used should be tailored 
individually according to tumor location and size, histol-
ogy, patient comorbidities and symptoms.21
Table 1 describes the main open approaches.11,12,18,19,22,23 
Lateral approaches via temporal craniotomy provide the short-
est corridor to the Meckel´s cave.12 Tumors originating intra-
cranially from the second (V2) or third (V3) division of the 
trigeminal nerve are better approached through a subtemporal 
preauricular infratemporal fossa approach (Figure 1).22,23 In 
tumors with a large extracranial component and anterior and 
inferior growth into the maxillary sinus, a facial translocation 
approach may be indicated (Figure 2).24,25 Transnasal endo-
scopic access to type A TS offers advantages similar to open 
skull base approaches in terms that there is no need for 
temporal lobe exposure or retraction with either technique, 
and both provide direct access to the tumor (Figure 2). 
Endoscopic approaches may provide a minimally invasive 
and safe approach to radically resect selected tumors.
Although the use of transpetrosal approaches for type 
B TS is under debate, the retrosigmoid approach is usually 
employed for posterior fossa tumors (Figure 1).11,12,18 In 
dumbbell shaped tumors (type C) with both posterior and 
middle fossa extension, in addition to a subtemporal 
approach a pre- or retrosigmoid craniectomy may provide 
additional exposure to resect.11,18
Schwannomas frequently do not invade nerve fibers 
but compress them. However, the nerve fibers are fre-
quently adherent to the tumor.15 MRI sequences will 
soon allow preoperative determination of whether the tri-
geminal nerve fibers are medial or lateral to the tumor. 
Transcranial approaches might then be chosen for tumors 
that displace the trigeminal nerve medially while endona-
sal techniques may be selected for tumors displacing the 
nerve laterally.26
The treatment aims of TS focus on improvement in 
neurologic symptoms, relief of mass effect, and 
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Table 1 Main Features of Non-Vestibular Intracranial Schwannomas
Location Frequency Classification Main Symptoms Other Symptoms/ 
Signs
Surgical Approach
TS 3–9% of intracranial 
schwannomas
-Type A: middle fossa (40%) 
-Type B: posterior fossa (22%) 














Visual loss (5–24%) 
FN weakness (0–20%) 
Hearing loss (5–30%) 





-Type A: transzygomatic extradural 
temporopolar/EEA 
-Type B: retrosigmoid 
-Type C: transzygomatic frontotemporal 
and retrosigmoid
LCNS −2.9–4% of all 
intracranial 
schwannomas 
-10–30% of tumors 
of the JF
-Type A: primarily intracranial 
(25–32%) 
-Type B: primarily within the JF 
(15–22%) 
-Type C: primarily extracranial 
(12–15%) 
-Type D (dumbbell-shaped): 
intra- and extracranial 
(40–68%)






(80–92% of the HS)
CN IX palsy (30–40%) 
CN X palsy (11–27%) 
CN XI palsy (9–17%) 
CN XII palsy (15–18%) 
CN VII palsy (8–18%)
-Type A: retrosigmoid 
-Type B: modified infratemporal fossa 
approach type A 
-Type D: Infratemporal fossa/transcoclear 
HS: far lateral/transcondylar





Canalicular segment (24.9%) 
Labyrinthine/geniculate 
segment (43.6%) 
Tympanic segment (42.2%) 
Mastoid segment (35.8%) 
Peripheral segment (14.6%) 








Ear canal mass (10.8%)
Pain (8.0%) 
Otorrhea (3.4%) 
Loss of taste (2.8%) 
Parotid mass (2.8%) 
Facial spasm (2.1%)
-Retrosigmoid approach in CPA tumors 
-Translabyrinthine approach in tumors 
from the brainstem to the mastoid 
-Middle cranial fossa approach for tumors 
between IAC and the tympanic segment 
-Transmastoid approach for tumors of the 
tympanic and segments
























Other cranial nerve 
palsies
Subtemporal transtentorial approach
ANS Cisternal (33%) 
Cisternocavernous (24%) 
Cavernous sinus (27%) 
Caverno-orbital (3%) 
Intraorbital (12%)







Signs of intracranial 
pressure
-Lesions involving cavernous sinus: 
frontotemporal transcavernous approach 
-Cisternal lesions: retrosigmoid approach
(Continued)
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preservation of cranial nerve function. After the applica-
tion of skull base techniques, gross total resection (GTR) 
has been achieved in 69–87%. Near GTR (4–26% of 
patients) or subtotal tumor resection (STR) (7–21% of 
patients) are performed when there are difficulties dissect-
ing tumor from cranial nerves, blood vessels, or the 
brainstem (Table 2).11,12,15,18,19,27 An improvement in 
facial pain post-operatively is seen between 45% and 
100% of cases;12,15,18,19 trigeminal hypesthesia improved 
in 16% to 62%.12,15,18,19 Temporalis and pterygoid func-
tion will rarely, if ever, fully improve when present pre- 
operatively.18,19 Other cranial nerve deficits, such as 
Table 1 (Continued). 
Location Frequency Classification Main Symptoms Other Symptoms/ 
Signs
Surgical Approach


















Abbreviations: TS, trigeminal nerve schwannoma; LCNS, lower cranial nerves schwannoma; FNS, facial nerve schwannoma; OMNS, oculomotor nerve schwannoma; TNS, 
trochlear nerve schwannoma; ANS, abducens nerve schwannoma; OGS, olfactory groove schwannoma; ONS, optic nerve schwannoma; EEA, endoscopic endonasal 
approach; CN, cranial nerves; JF, jugular fossa; HS, hypoglossal schwannoma; SRS, stereotactic radiosurgery; CPA, cerebellopontine angle; IAC, internal auditory canal; HB, 
House-Brackman; CN, cranial nerves.
Figure 1 Surgical approaches in trigeminal schwannomas: subtemporal-preauricular and transcochlear. (A) Type ME2 TS with massive involvement of the middle cranial 
fossa and the infratemporal fossa (*). (B) Postoperative CT showing the resection of the tumor through a subtemporal-preauricular approach. (C) T1-weighted MRI of 
a Type P TS in the posterior cranial fossa (*). (D) T1-weighted MRI with contrast showing total resection of the tumor through a transcochlear approach. The operative 
cavity is filled by fat (*).
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diplopia caused by palsy of the abducens nerve, improved 
in 44–75% of patients,12,17–19 However surgical injury to 
the abducens nerve (8%), trochlear nerve (3.7%), and 
oculomotor nerve (1.9%) has been reported.28 Long tract 
and cerebellar signs disappeared in 78–100%.15,17–19 
Severe surgical complications are rare (<2% of cases) 
and include meningitis, cerebrospinal fluid (CSF) leak, 
arterial vasospasm, hematoma, and 
hydrocephalus.9,11,18,19 The overall mortality rates of sur-
gical series reported since 1990 range from 0 to 
3%.11,12,19,27,29,30 The sensory and motor outcomes of 
endoscopic approaches compare favorably with open sur-
gical approaches. However, some patients may develop 
dry eye, as a result of vidian nerve sacrifice.31
Stereotactic radiosurgery (SRS) is an alternative to surgery. 
Most of series report a tumor control rate greater than 80%, 
which is somewhat lower than that achieved with vestibular 
schwannomas.3,26,32–34 The incidence of tumor regression 
ranges from 34% to 87% and tumor stability from 8% to 
50%.32–37 A significant symptomatic improvement following 
SRS varies from 31% to 72% across the series, whereas the 
incidence of symptomatic deterioration varies from 0% to 
27%.9 The factors affecting outcomes include tumor size and 
site, radiation dose and the radiological appearance of the mass 
(solid or cystic). The optimal tumor marginal dose appears to 
be 13–16 Gy. SRS is associated with a very low risk of a new 
neurologic deficit or other type of complications (less than 
16% of patients) (Table 3).32–37 There has been speculation 
regarding the risk of malignancy after treatment with SRS. 
With a median follow-up of 8.1 years, 2 of 3251 (0.0006%) 
patients with benign tumors treated with SRS were diagnosed 
with suspected malignant transformation and 1 of 4905 
(0.0002%) patients was considered a case of radiosurgery- 
associated intracranial malignancy, resulting in an incidence 
of 6.87 per 100,000 patient-years for malignant transformation 
and 2.26 per 100,000 patient-years for radiosurgery-associated 
intracranial malignancy, similar to the risk of developing 
a malignant CNS tumor in the general population.38
Figure 2 Surgical approaches in trigeminal schwannomas: EEA and facial translocation approach. (A) T2-weighted MRI of a Type ME1 TS. The tumor is in contact with the 
transition between ethmoidal cells and the sphenoid sinus (*). (B) Tumor into the Meckel’s cave (*). (C) Orbital progression in a T1-weighted MRI (*). This tumor was 
excised through an EEA. (D) T1-weighted MRI with contrast of an extensive dumbbell-shaped tumor (*) Type ME2 involving the middle and infratemporal fossae as well as 
the maxillary sinus. (E) T1-weighted MRI with contrast of a TS with a similar pattern of extension (*). (F) Postoperative CT scan of the anterior case showing the removal of 
the tumor. The operative cavity was obliterated with a temporalis muscle flap (*).
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Small lesions with few, if any, symptoms may be 
managed with watchful waiting. Makarenko et al observed 
8 patients with TS; an 11.1% progressed over a median of 
7.1 years.39
Lower Cranial Nerves 
Schwannomas (LCNS)
Epidemiology
Among NVCNS, LCNScomprise the second most com-
mon site after TS. LCNS can originate intracranially or 
in the cervical region. Intracranial LCNS usually 
extend to the jugular foramen or the hypoglossal 
canal. Jugular foramen schwannomas arising from cra-
nial nerves IX, X or XI are rare and comprise 2.9% to 
4% of all intracranial schwannomas, and represent 
10–30% of all tumors observed around the jugular 
foramen.40,41 In a review of 204 patients, the tumor 
originated from the glossopharyngeal nerve (IX) in 47 
cases (23.6%), in 26 cases (13%) from the vagal nerve 
(X) and in 11 cases (5.5%) from the accessory nerve 
(XI). In the remaining 58% of the cases, the origin of 
the tumor remained unknown.40 Hypoglossal schwan-
nomas (HS) constitute only about 1% of all intracranial 
schwannomas.42
Table 2 Main Surgical Series of Intracranial Schwannomas




Near Total or Subtotal 
Removal (%)




Konovalov et al27 TN 111 77 23 13 3
Goel et al19 TN 73 70 30 31 2,7
Wanibuchi et al12 TN 105 75 25 9 0
Chen et al18 TN 55 69 31 5 0
Liu et al11 TN 84 75 25 12 0
Yoshida & Kawase16 TN 27 67 33 52 0
Sharma et al30 TN 68 76 24 15 1,5
Day & Fukushima14 TN 39 77 23 16 0
Jeong et al29 TN 49 92 8 41 0
Cornelius et al55 FN 10 70 30 60 0
Sherman et al56 FN 10 90 10 20 0
Bakar40 LCN* 199 79 21 38 0,5
Bulsara et al53 LCN 53 90 10 62 0
Abbreviations: TN, trigeminal nerve; FN, facial nerve; LCN, lower cranial nerves. *Systematic review of 19 series.
Table 3 Main Stereotactic Radiosurgery Series of Intracranial Schwannomas










Elsharkawy et al32 All locations NVCNS 36 56 25 19 12
D’Astous et al3 All locations NVCNS 63 57 35 8 6
Peker et al33 TN 15 87 13 0 7
Ryu et al34 TN 32 34 50 16 16
Snyder et al35 TN 22 54 23 23 16
Pan et al36 TN 56 85 8 7 7
Sun et al37 TN 52 77 10 13 4
Kida et al63 FN 14 57 43 0 7
Hasegawa et al62 FN 42 55 45 3 12
Hasegawa et al80 LCN 117 53 36 11 7
Kano et al79 LCN 92 51 36 13 15
Martin et al81 LCN 34 48 46 6 3
Peciu-Florianu et al65 OMNS/TNS/ANS 30 63 36 3 0
Abbreviations: NVCNS, non-vestibular cranial nerves schwannomas; TN, trigeminal nerve; FN, facial nerve; LCN, lower cranial nerves; OMNS, oculomotor nerve 
schwannoma; TNS, trochlear nerve schwannoma; ANS, abducens nerve schwannoma.
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Classification
Pellet et al classified jugular foramen schwannomas into 4 
classes.43 Type A (primarily intracranial): minimal exten-
sion into the jugular foramen; type B (primarily within the 
bone): with or without an intracranial component; type 
C (primarily extracranial): only a minor extension into 
the jugular foramen or into the posterior fossa; and type 
D (dumbbell-shaped): intra- and extracranial extension. 
According to Pellet’s classification, type 
Dschwannomas are the most common (40–68%), followed 
by type A (25–32%), type B (15–22%) and type 
C (12–15%).40,44
HS have been classified by Kaye et al45 in type A: 
intradural tumor; type B: dumbbell-shaped tumor; and 
type C: extracranial tumor. In 2 reviews of the literature 
consisting of 94 and 160 cases, the following distribution 
has been reported: type A, 29–32%; type B, 39–50%; and 
type C, 21–29%.42,46
Symptoms and Signs
Hearing impairment is the most frequent presenting symp-
tom in intracranial and jugular foramen LCNS.40,41,43,47 
Most of patients show a mid-frequency hearing loss, in 
contrast to the high-frequency hearing loss observed with 
VS.47 Type A tumors may cause symptoms related to 
increased intracranial pressure, without or with minimal 
deficits of the lower cranial nerves, whereas a tumor 
expanding into the jugular foramen or upper cervical 
region might cause earlier damage of the nerves.41 Other 
presenting symptoms are shown in Table 1.
HS are characterized by tongue atrophy. Lower cranial 
nerves are affected in up to 50% of the cases, mainly in 
tumors with extension to the jugular foramen.45,46
Management
Schwannomas generally arise in nerves with a sensory 
component and are associated with sensory ganglia. In 
the case of the vagal nerve, tumors are likely to involve 
sensory nerves and it is possible to preserve their function 
with an intracapsular enucleation, which can increase the 
neural function preservation by more than 30%.7,48 
Continuous vagal nerve monitoring during surgery is 
a new strategy developed with the aim of reducing post-
operative morbidity.49
Table 1 summarizes the main surgical approaches used 
in LCNS resection according to their location.40,50–52 For 
tumors confined intracranially (type A), a retrosigmoid 
approach may provide adequate exposure (Figure 3). In 
tumors centered in the jugular foramen (type B) or with 
extracranial extension the modified infratemporal fossa 
approach type A (ITFA) provides the greatest exposure 
of the jugular foramen, carotid artery, and anterior tem-
poral bone and it allows direct access to the posterior fossa 
(Figures 3 and 4).51,52 Other skull base techniques such as 
far lateral, transcondylar, and supracondylar approaches 
have been advocated for the surgical excision of HS 
(Figure 4).41,45,46
Bakar40 reviewed the outcomes obtained after the sur-
gical treatment of 204 patients. He reported a GTR in 
86.9% of the patients, near GTR in 3.3% of the patients 
and STR in 9.8% of the patients (Table 2).40 Park et al44 
analyzed the results of surgery in 275 cases collected in 
large series of jugular foramen schwannomas and found 
postsurgical lower cranial nerve palsies in 34.9% of the 
patients. New neurological deficits are common, especially 
involving the facial nerve, which was reported in 6–34% 
of cases40,43,47 Other reported complications include CSF 
leak (3–7%), aspiration pneumonia (1.5–6%), venous 
sinus thrombosis (3%), and meningitis (2%). 
Postoperative mortality ranges between 0.5% and 
5%.40,46,53
Near GTR followed by SRS or SRS alone offers an 
alternative approach in some patients (Tables 3 and 4). 
There are limited data based largely on extracranial 
schwannomas that fractionated external beam radiotherapy 
(RT) using doses of approximately 50 Gy at 1.8 Gy per 
fraction results in a high likelihood of local control.54 RT 
usually induces cessation of lesion growth or reduction in 
size, rather than complete disappearance of the tumor, 
which is the goal of the surgical intervention. Side effects 
are negligible when doses are 50 Gy or less and modern 
precision RT techniques are used. This is additional option 
for patients requiring treatment who are unsuitable for 
surgery.
Observation is another option in asymptomatic 
patients, particularly for those who are elderly and/or 
infirm.
Facial Nerve Schwannomas (FNS)
Classification
About 650 cases of FNS have been reported in the literature.55 
The site of origin can be anywhere along the course of the 
facial nerve from the glial-Schwann cell transition site at the 
cerebellopontine angle to an extracranial peripheral nerve 
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location. They have been classified based on their site of 
origin into cerebellopontine angle (CPA), labyrinthine, geni-
culate, tympanic, mastoid, and parotid segments (Figure 5).56 
The percentage involving each segment in a review of 438 
cases was reported by Cornelius et al (Table 1).55
It is imperative to include FNS in the differential 
diagnosis of VS during preoperative planning and counsel-
ing. However, this is often difficult to achieve pre- 
operatively, even with a careful evaluation of the MRI 
and computed tomography (CT). FNS involving the CPA 
and/or the IAC segment of the FN cannot be differentiated 
from a VS on imaging unless the tumor extends to the 
labyrinthine segment of the FN. Erosion of superior part of 
the internal auditory canal and eccentricity of tumor in 
relation to porus acousticus are not reliable signs. 
However, facial paralysis is a sign that would support the 
origin in the facial nerve since VS presenting with facial 
paralysis is rare.
Symptoms and Signs
The growth rate of FNS is slow. Thus, in a series of 13 
patients treated expectantly with a mean follow-up period 
of 5 years, only 4 demonstrated tumor growth based on 
serial MRs. The average annual growth rate was 1.4 mm/ 
year.57
Patients frequently present with facial nerve weakness 
[House-Brackmann (HB) III or IV], as well as hearing 
loss.58–60 Tumors located at CPA usually present with 
sensorineural hearing loss (SNHL) and tinnitus instead of 
facial paresis. Patients with tumors originating from the 
labyrinthine segment tend to present with slowly progres-
sive facial paresis and SNHL, whereas patients with 
tumors of the tympanic and mastoid segments show pro-
gressive facial paresis and conductive hearing loss. The 
Figure 3 Surgical approaches in lower cranial nerve schwannomas. (A) T1-weighted MRI with contrast of a Type A cystic vagal schwannoma (*). (B) T1-weighted MRI with 
contrast of a Type A vagal schwannoma (*). (C) Retrosigmoid approach of the last case showing the tumor (1) and the cochleo-vestibular nerve (2). (D) Coronal T2- 
weighted MRI delimiting a Type B lower cranial nerve schwannoma in the jugular fossa (*). (E) Axial T1-weighted MRI with contrast of the same tumor (*). (F) Modified 
infratemporal fossa approach type (A) internal carotid artery (1), third portion of the facial nerve (2), tumor in the jugular fossa (3).
Figure 4 Lower cranial nerve schwannomas with intra- and extracranial extension. 
(A) T1-weighted MRI with contrast of a Type D vagal schwannoma (*). (B) T1- 
weighted MRI with contrast of a Type B hypoglossal schwannoma (*).
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distribution of presenting symptoms in 438 patients with 
FNS is depicted in Table 1.55
Management
If the patient is asymptomatic and the tumor is small, con-
servative management with careful observation and follow- 
up with serial MRI are recommended. SRS may be an 
option for small and symptomatic tumors with good facial 
function (HB I or II). If the tumor is larger (more than 3 cm) 
or the patient has facial palsy (HB III or worse), surgical 
resection should be considered.61 Alternatively, fractio-
nated RT is an option if the anticipated morbidity of surgery 
is significant. The surgical approach depends on the tumor 
location and extent. The retrosigmoid approach permits 
access to the nerve from the brainstem to the IAC and 
allows resection of large tumors in the CPA. The transla-
byrinthine approach gives access to the entire nerve course 
from the brainstem to the stylomastoid foramen. This 
approach may only be chosen if hearing is not serviceable 
or if tumor volume or inner ear erosion makes hearing 
preservation impossible. A middle cranial fossa approach 
allows access to the nerve between IAC and the proximal 
tympanic segment. Combining this approach with 
a transmastoid approach the entire nerve from the IAC to 
the stylomastoid foramen can be exposed. Hearing preser-
vation is possible by employing this route that make if 
possible, to repair ossicular chain defects.55
There are different options to preserve the facial nerve 
function: nerve conservation, nerve resection with 
immediate grafting, or hypoglossal-facial nerve 
anastomosis.59 Nerve preservation has been reported in 
58–71% of the patients.55–57 However, facial nerve func-
tion was, in the majority of cases, a HB grade III, depend-
ing on surgical strategy (Table 2).58,60 Regardless of the 
type of facial nerve repair, patients can expect no better 
than an eventual HB grade III palsy.58,59
SRS achieves a good tumor control rates.62,63 Thus, 
a multi-institutional study reported 42 patients treated with 
SRS, with partial regression in 23 patients (54.7%) and 
stability in 19 patients (45.2%) (Table 3). The actuarial 
5-year progression-free survival rate was 92%.63
Oculomotor Nerve Schwannomas 
(OMNS)
Classification
There are only 54 cases of isolated OMNS reported in 
indexed literature.64 The transition of the oculomotor 
nerve from the central to the peripheral nervous system 
occurs 0.6 mm distal to the brainstem. OMNS develop 
distal to this transition zone. OMNS have been divided 
into 4 types based on their location: cisternal, caver-
nous, cisterno-cavernous, and orbito-cavernous 
(Table 1).65,66
Table 4 Radical Resection versus More Conservative Management
Author Location No. Cases Total Removal Subtotal Removal + 
SRS
Newly Developed Cranial 
Nerve Palsies
Mortality
Park et al44 LCN 22 13 23 0
LCN 22 9 4 0
Author Location No. Cases Total Removal 
%
Near Total or Subtotal 
Removal %
Increased or Newly 
Developed Morbidity %
Mortality
Sedney et al77 LCN 53 90 10 62 0
LCN 28 24 76 25 0




Worsened Facial Function % Mortality
Liu  & Fagan82 FN 22 12 50 0
FN 22 10 20 0
McMonagle 
et al83
FN 53 33 33 0
FN 53 20 15 0
Abbreviations: FN, facial nerve; LCN, lower cranial nerves.
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Symptoms and Signs
The clinical features depend on the location of the tumor 
with cisternal schwannomas showing isolated deficits of 
the nerve. When these tumors originate into the cavernous 
sinus, they can present with either a cavernous sinus 
syndrome or an orbital apex syndrome. Symptoms can 
vary from incomplete oculomotor palsy and exophthalmos 
to brainstem compression signs.65 A systematic review has 
summarized the most frequent symptoms (Table 1).64
Management
Treatment for OMNS remains multimodal, depending on 
clinical presentation, tumor size, histology, and location. 
A careful preoperative evaluation including MR guides in 
distinguishing different histologies. Although most tumors 
arising from the oculomotor nerve are well encapsulated 
schwannomas and, in a few cases, nerve sparing surgery 
may be possible, neurofibromas have also been described. 
Neurofibromas tend to invade the entire nerve fibers and 
always require the complete sacrifice of the nerve.67
Often microsurgery remains the treatment of choice for the 
GTR of cisternal schwannomas after identification of the nerve 
of origin. However, when tumors are located in the cisterno- 
cavernous area, total removal of tumor and identification of the 
parent nerve is barely achieved in half of the cases and 
a combined approach with STR and SRS should be 
employed.68 Tumors with small-to-medium sized volumes 
are preferably treated by SRS with a high rate of tumor control 
and stabilization and/or improvement of symptoms.65
Functional recovery of the oculomotor nerve after STR is 
successful in less than 10% of the patients. Since the oculomotor 
nerve innervates multiple ocular muscles, the functional result 
after nerve anastomosis may be limited, and aberrant regenera-
tion may interfere with coordinated binocular movements.64
Trochlear Nerve Schwannomas 
(TNS)
Classification
A total of 85 cases reporting on the management of TNS 
have been published.66 Three types of TNS have been 
described: cisternal type, cisterno-cavernous type, and the 
cavernous type. In more than half of the cases reported so 
far, the cisternal type was diagnosed.65,66
Symptoms and Signs
According to a systematic review from Torun et al66 76% of 
the entire cohort presented with diplopia, which was the 
solitary symptom in over half of the cases, and 29% of 
cases presented with more severe symptoms, such as paresis, 
sensory changes, ataxia, and other cranial nerve palsies.66
Management
All symptomatic patients with a lesion exerting significant 
mass effect should undergo decompression. The most 
widely employed microsurgical approach has been the 
subtemporal transtentorial approach. Nevertheless, nearly 
80% of those with surgical resection had persistent tro-
chlear nerve palsy at the last follow-up.
SRS is a good option for patients presented with diplopia only, 
and 75% of the patients show improved symptoms after therapy.66
Patients who only have stable ocular misalignment due to 
trochlear nerve palsy can also be managed with prism glasses 
to alleviate diplopia or may choose to undergo strabismus 
surgery, combined with observation and serial MR imaging.66
Abducens Nerve Schwannomas 
(ANS)
Classification
ANS form an extremely rare entity with only 33 surgical 
cases published to date69 and 16 cases treated by SRS.65 
The most common locations are shown in Table 1.69,70
Figure 5 Facial nerve schwannomas. (A) The CT scan shows a tumor involving the 
tympanic and geniculate segments of the facial nerve (arrows), with displacement of 
the ossicular chain. (B) Small tumor limited to the tympanic segment (arrow). (C) 
T1-weighted MRI with contrast of a facial nerve schwannoma of the geniculate 
ganglion (arrow). (D) Transtemporal approach. Geniculate ganglion schwannoma 
(*), petrous pyramid (1), dura (2).
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Symptoms and Signs
The cardinal neurological sign of ANS is diplopia in the 
horizontal gaze. However, patients may be asymptomatic 
or present with headache, proptosis, other oculomotor and/ 
or trigeminal signs, and signs of increased intracranial 
pressure.65 Involvement of other cranial nerves has been 
noted in over half the patients.69
Management
Surgical resection is indicated in symptomatic patients 
with neurological deficits, and most importantly to relieve 
any mass compression of surrounding structures.69 Extra- 
cavernous extension involving the orbital apex, superior 
orbital fissure and petroclival junction limits complete 
resectability. GTR with graft reconstruction of the abdu-
cens nerve has been recommended,69 but gross involve-
ment of the cavernous sinus make more convenient to 
achieve a STR in order to avoid additional neurological 
damage. A frontotemporal transcavernous approach has 
been suggested for cavernous sinus and parasellar lesions, 
whereas the retrosigmoid approach is indicated for tumors 
involving the prepontine region.71 In a systematic analysis, 
Sun et al69 have reported abducens nerve recovery in less 
than half of the patients (45%). Tumor extension to the 
cavernous sinus was significantly associated with a lower 
likelihood of postsurgical recovery.
SRS (single dose of 12.0–12.5 Gy) is recommended for 
small and moderate size tumors. Tumor volume was 
reported to remain stable in 18%, reduced in 37%, and 
increased in 12% of the patients, respectively (not reported 
in 31%), treated with gamma knife SRS.65
Olfactory Groove Schwannomas 
(OGS)
Histogenesis
Thus far, only 46 cases with an OGS have been reported.8 
Schwannomas of the olfactory bulb are uncommon as the 
olfactory nerve is unsheathed by Schwann cells. There 
have been various hypotheses proposed to explain the 
origin of OGS: the developmental hypothesis suggesting 
transformation of mesenchymal pial cells into ectodermal 
Schwann cells, and the non-developmental theory stating 
that these schwannomas may arise from Schwann cells of 
adjacent normal structures, such as Schwann cell hyper-
plasia occurring within the perivascular nerve 
plexuses.59,72 In contrast, neural crest cells have the ability 
to transform to other cells in the line or acquire abilities 
from some of these.73
Symptoms and management
In most reported cases of OGS, the chief complaints were 
headache, vomiting, seizure, diplopia, hyposmia or anos-
mia (Table 1).8,59
Surgery, either transfrontal or endoscopic, is the pre-
ferred treatment for olfactory schwannoma. GTR done by 
careful extra-arachnoidal dissection is possible as the 
tumor is well encapsulated and a plane of cleavage from 
olfactory tract is often present thus allowing 
preservation.59
Optic Nerve Schwannomas (ONS)
Histogenesis
Schwannomas partially located in the optic canal with an 
orbital and/or cisternal component are rare with only few 
cases reported, but those confined entirely within the optic 
canal are much rarer. As the optic nerve is in fact a part of 
the central nervous system, it is myelinated by central 
nervous system oligodendrocytes rather than Schwann 
cells.1,74 ONS originate from ectopic Schwann cells 
around the optic nerve or from the sympathetic nerves 
around the optic nerve in the orbit, probably originating 
from peripheral sympathetic nerves innervating the central 
retinal artery or the carotid artery.1,74
The microscopic appearance of schwannomas of the 
optic nerve is the same as for all schwannomas of periph-
eral nerve origin, thus distinguishing them from similar 
appearing lesions, such as optic nerve gliomas or menin-
giomas. Optic nerve sheath schwannomas probably cannot 
be diagnosed on clinical grounds alone, and their neuroi-
maging appearance mimics that of the more common optic 
nerve gliomas and the diagnosis is usually made at 
surgery.75
Symptoms and Management
Clinical presentation of lesions arising in the optic nerve is 
nonspecific and ranges from insidious proptosis, severe 
visual acuity disturbance and/or visual field defect, retro- 
orbital pain and headaches, to in rare cases blindness. 
Since the optic canal is a narrow bony structure with 
a mean diameter of 4 mm, the optic nerve can be com-
pressed by even a tiny tumor.
The tumor can be approached extradurally by drilling 
the anterior clinoid and unroofing the optic canal. Orbital 
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tumors may be safely and effectively resected via a various 
number of approaches. Currently, a transorbital endoscopic 
approach alone or combined with an expanded endoscopic 
endonasal approach is proposed as a method to improve 
visualization and maximize instruments’ maneuverability. 
Nevertheless, traditional external approaches, with differ-
ent skin or trans-conjunctival incisions, represent an effec-
tive and sound surgical option for the management of these 
lesions.74,76 SRS would be not be indicated because of the 
risk of optic neuropathy associated with a single large 
fraction of irradiation. Patients unsuitable for sur-
gery may be considered for fractionated proton irradiation 
to provide a high likelihood of tumor control while mini-
mizing the dose to the retina.
Discussion
In the era of personalized medicine, trends in NVCNS 
management are giving way to a more individualized 
treatment plan based on the combination of surgery, radia-
tion therapy and/or observation.
Because NVCNS are benign tumors, complete surgi-
cal excision while avoiding functional and aesthetic 
sequelae, is a primary objective. Despite the progress 
made in surgical approaches, resection is still associated 
with some morbidity in certain circumstances. The treat-
ment goals for NVCNS are heavily dependent on the 
tumor presentation, location, histology and size.67 In 
addition, patient characteristics such as age and comor-
bidities must be taken into account. Not all patients 
should be operated, and surgery would not be an option 
if the risks are greater than those of a non-surgical treat-
ment or observation. When dealing with tumors invol-
ving critical structures (i.e.: cavernous sinus, optic nerve, 
jugular fossa, etc.), whose damage has a significant 
impact on quality of life, management decisions must 
be individualized. Although some authors have reported 
improvement of symptoms with GTR, in most cases the 
presenting symptoms persisted or worsened after surgical 
resection.31
In older and in asymptomatic patients with small 
tumors, when imaging studies and examination strongly 
suggest a benign tumor, close surveillance may be consid-
ered even without histological evidence, to avoid the risks 
inherent in biopsy or surgical resection. Likewise, asymp-
tomatic patients with slow-growing small tumors should 
be managed with caution because they are at high risk of 
cranial nerve damage if operated on. In these cases, sur-
gery should be avoided if it is expected to cause high 
morbidity. Gradual loss of nerve function is usually better 
tolerated than sudden loss as a result of surgery, so obser-
vation or deferral of surgery is recommended in patients 
without neurological alterations.
Safer treatment options have been proposed in some 
cases. RT has been used as either a primary or an adjunct 
treatment for NVCNS and offers the advantages of a high 
tumor control rate and a low rate of radiation associated 
complications. In contrast to surgical resection, injuries to 
the brain, vascular, or other cranial nerves are unlikely. 
SRS may offer therapeutic advantages over conventional 
RT, particularly logistically because it employs one frac-
tion as opposed to 5 to 6 weeks of daily fractionated RT. 
Additionally, a tighter margin is employed with SRS so 
that less normal tissue is irradiated. Disadvantages of SRS 
are that the risk of a neurologic deficit may be higher due 
to the large dose per fraction and the risk of a marginal 
miss may be increased.
Patients with small- to moderate-sized tumors with 
intact cranial nerve function are optimal candidates for 
SRS. Furthermore, symptoms related to cranial nerve dys-
function may improve after SRS. In addition, patients with 
previous contralateral neurological deficits of the lower 
cranial nerves may not be suitable for surgery because of 
the risk that bilateral deficits will cause problems with 
swallowing and laryngeal mobility. In these cases, SRS 
may be useful. However, it is important to note that some-
times small-sized and slow-growing tumors are very 
symptomatic, and the symptoms are refractory to medical 
treatment (i.e., TNS refractory to carbamazepine). In these 
cases, surgical treatment is safer than follow-up or SRS. 
RT has been also used for patients who present large 
tumors or tumors affecting critical areas with high surgical 
morbidity. Residual tumor after surgery should be treated 
and SRS or RT are good options with acceptable 
morbidity.
When it is not possible to achieve a GTR because of 
technical operative difficulties or when surgery causes 
significant morbidity, STR or near GTR followed by 
SRS is gaining acceptance. Concerning TS, Pan et al36 
reported that tumor growth control in 56 patients treated 
by using SRS, was obtained in 93% of the patients 
(including patients who had previously undergone STR). 
Cranial nerve preservation in patients with LCNS extend-
ing to the jugular foramen is challenging. Lower cranial 
neuropathies can severely affect quality of life requiring 
tracheostomy or gastrostomy. Park et al44 reported on 13 
patients with LCNS treated with GTR and 9 patients 
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treated by STR followed by SRS. In the latter group, 4 
patients (44%) showed a reduction in tumor size and 5 
patients (56%) showed no evidence of tumor progression. 
Postoperative CN deficits were higher in the GTR group 
(23 vs. 4 CNs affected, respectively). In addition, patients 
treated by STR and SRS showed a statistically significant 
improvement in the level of dysphagia. Sedney et al77 
compared the outcomes of 53 LCNS patients who under-
went a GTR with 28 patients receiving a more conserva-
tive resection. There was a statistically significant 
decrease in permanent deficits of CN IX/X with 
a conservative technique, whereas the recurrence rate 
was similar in both series (Table 4). The satisfactory 
clinical results obtained support that an appropriate strat-
egy in the management of some LCNS is surgical resec-
tion to reduce tumor size followed by SRS in situations 
where GTR would likely cause significant morbidity.78–81 
We believe that this alternative is potentially safe and 
effective and should be considered.
The best timing for surgery in FNS is controversial: it 
depends on facial nerve function, hearing, size, intracra-
nial mass effect and patient choice. If hearing remains 
good and there is no threat from intracranial mass effect, 
observation until HB III is possible and radical tumor 
excision may be performed then. The reason is that even 
for good preoperative facial function (HB I–II) and 
regardless of the grafting technique, no better postopera-
tive result than HB-III can be expected, although it is 
possible to preserve the nerve in approximately 25% of 
cases if the tumor is located eccentrically on the nerve.61 
Liu and Fagan82 analyzed a series of 22 patients with 
FNS, of whom 12 underwent definitive excision and 10 
were managed more conservatively. The best postopera-
tive facial function in the group where the tumor was 
removal was a HB-III, while in the group treated con-
servatively, 8 had normal facial function. The role of 
“wait and see” approach has been evaluated by 
McMonagle et al83 in a series of 53 patients with FNS 
where 20 patients were managed conservatively and 33 
underwent surgery. There was a GTR in 21 cases and 
near GTR was obtained in 12 cases. HB grade remained 
stable in all patients in whom no removal or STR was 
undertaken, while it worsened in 55% of patients receiv-
ing GTR. They conclude that observation is preferred 
until facial function deteriorates to a HB-III (Table 4). 
Another alternative is RT to avoid facial nerve deteriora-
tion and have a high likelihood of tumor control. 
Wilkinson et al84 reported a series of patients with 
FNS; through 1995, 85% of cases had surgical resection 
and none had observation only. Of the patients seen after 
1995, 27% had surgical resection and grafting, 33% had 
bony decompression, 29% were managed with observa-
tion alone, and 11% had RT. Facial nerve grade was 
maintained or improved over the follow-up period in 
78.9% of the decompression group and 100% of the 
observation and RT groups, compared to 54.8% of the 
resection group (P < 0.012). The trend is towards con-
servative management of these tumors.
Figure 6 Steps in the management of non-vestibular skull base and intracranial schwannomas.
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Conclusion
NVCNS are rare tumors with a diversity of clinical man-
ifestations, depending on the location and cranial nerve of 
origin. Management decisions are based on tumor size and 
functional deficits. The treatment of choice is total surgical 
resection, but SRS or RT are alternatives in those cases 
where surgical resection would be associated with sub-
stantial morbidity. Given the slow growth rate of most of 
these tumors, observation is also an alternative in asymp-
tomatic patients (Figure 6).
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